These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27657807)

  • 1. New potent biaryl sulfate-based hepatitis C virus inhibitors.
    You Y; Kim HS; Bae IH; Lee SG; Jee MH; Keum G; Jang SK; Kim BM
    Eur J Med Chem; 2017 Jan; 125():87-100. PubMed ID: 27657807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.
    Abdallah M; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Bartenschlager R; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Eur J Med Chem; 2022 Feb; 229():114034. PubMed ID: 34959173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives.
    Kakarla R; Liu J; Naduthambi D; Chang W; Mosley RT; Bao D; Steuer HM; Keilman M; Bansal S; Lam AM; Seibel W; Neilson S; Furman PA; Sofia MJ
    J Med Chem; 2014 Mar; 57(5):2136-60. PubMed ID: 24476391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
    Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
    You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
    RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.
    Giroux S; Bilimoria D; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Henderson JA; L'Heureux L; Mani N; Morris M; Nicolas O; Reddy TJ; Selliah S; Shawgo RS; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):940-3. PubMed ID: 25597006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5731-5737. PubMed ID: 25453810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
    Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
    Henderson JA; Bilimoria D; Bubenik M; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Falardeau G; Giroux S; L'Heureux L; Liu B; Mani N; Morris M; Nicolas O; Pereira OZ; Poisson C; Reddy TJ; Selliah S; Shawgo RS; Vaillancourt L; Wang J; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):948-51. PubMed ID: 25577039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).
    Ivachtchenko AV; Mitkin OD; Yamanushkin PM; Kuznetsova IV; Bulanova EA; Shevkun NA; Koryakova AG; Karapetian RN; Bichko VV; Trifelenkov AS; Kravchenko DV; Vostokova NV; Veselov MS; Chufarova NV; Ivanenkov YA
    J Med Chem; 2014 Sep; 57(18):7716-30. PubMed ID: 25148100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
    Lopez OD; Nguyen VN; St Laurent DR; Belema M; Serrano-Wu MH; Goodrich JT; Yang F; Qiu Y; Ripka AS; Nower PT; Valera L; Liu M; O'Boyle DR; Sun JH; Fridell RA; Lemm JA; Gao M; Good AC; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Feb; 23(3):779-84. PubMed ID: 23273521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
    Belema M; Nguyen VN; Bachand C; Deon DH; Goodrich JT; James CA; Lavoie R; Lopez OD; Martel A; Romine JL; Ruediger EH; Snyder LB; St Laurent DR; Yang F; Zhu J; Wong HS; Langley DR; Adams SP; Cantor GH; Chimalakonda A; Fura A; Johnson BM; Knipe JO; Parker DD; Santone KS; Fridell RA; Lemm JA; O'Boyle DR; Colonno RJ; Gao M; Meanwell NA; Hamann LG
    J Med Chem; 2014 Mar; 57(5):2013-32. PubMed ID: 24521299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.